Paper41689691
Neuroendocrine prostate cancer (NEPC) in focus: state of the art and future prospectives.
Giunta EF and 8 others. Discov Oncol, 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Neuroendocrine prostate cancer (NEPC) in focus: state of the art and future prospectives. Papers, record 41689691. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41689691
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Neuroendocrine prostate cancer (NEPC) in focus: state of the art and future prospectives.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References112
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32802517 | Interleukin-10 Induces Expression of Neuroendocrine Markers and PDL1 in Prostate Cancer Cells. | Prostate Cancer | 2020 | https://conductscience.org/library/papers/32802517 | PubMed |
| 2 | 11713282 | Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. | Mol Cell Biol | 2001 | https://conductscience.org/library/papers/11713282 | PubMed |
| 3 | 22294438 | Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. | J Pathol | 2012 | https://conductscience.org/library/papers/22294438 | PubMed |
| 4 | 39498180 | A case of mixed neuroendocrine carcinoma-acinar adenocarcinoma: Utilization of triplet therapy for prostate cancer. | IJU Case Rep | 2024 | https://conductscience.org/library/papers/39498180 | PubMed |
| 5 | 23649003 | Platinum-based chemotherapy for variant castrate-resistant prostate cancer. | Clin Cancer Res | 2013 | https://conductscience.org/library/papers/23649003 | PubMed |
| 6 | 40969278 | Mechanism of action of HMGB1 in urologic malignancies. | Front Oncol | 2025 | https://conductscience.org/library/papers/40969278 | PubMed |
| 7 | 23228172 | Abiraterone in metastatic prostate cancer without previous chemotherapy. | N Engl J Med | 2013 | https://conductscience.org/library/papers/23228172 | PubMed |
| 8 | 39195285 | Impact of Neuroendocrine Differentiation (NED) on Enzalutamide and Abiraterone Efficacy in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Retrospective Analysis. | Cells | 2024 | https://conductscience.org/library/papers/39195285 | PubMed |
| 9 | 24705311 | Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. | Am J Surg Pathol | 2014 | https://conductscience.org/library/papers/24705311 | PubMed |
| 10 | 34771657 | Dipeptidyl Peptidase Inhibition Enhances CD8 T Cell Recruitment and Activates Intrahepatic Inflammasome in a Murine Model of Hepatocellular Carcinoma. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34771657 | PubMed |
| 11 | 35983951 | DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. | Oncologist | 2022 | https://conductscience.org/library/papers/35983951 | PubMed |
| 12 | 30188869 | Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy. | J Clin Invest | 2018 | https://conductscience.org/library/papers/30188869 | PubMed |
| 13 | 40689871 | Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study. | Clin Cancer Res | 2025 | https://conductscience.org/library/papers/40689871 | PubMed |
| 14 | 29297494 | Neuroendocrine tumors of the prostate. | Mod Pathol | 2018 | https://conductscience.org/library/papers/29297494 | PubMed |
| 15 | 36351060 | Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer. | Cancer Res | 2023 | https://conductscience.org/library/papers/36351060 | PubMed |
| 16 | 25450825 | Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. | Biochim Biophys Acta | 2014 | https://conductscience.org/library/papers/25450825 | PubMed |
| 17 | 9860977 | A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells. | Proc Natl Acad Sci U S A | 1998 | https://conductscience.org/library/papers/9860977 | PubMed |
| 18 | 29985747 | Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. | J Clin Oncol | 2018 | https://conductscience.org/library/papers/29985747 | PubMed |
| 19 | 31525487 | Clinical features of neuroendocrine prostate cancer. | Eur J Cancer | 2019 | https://conductscience.org/library/papers/31525487 | PubMed |
| 20 | 31515154 | Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. | Lancet Oncol | 2019 | https://conductscience.org/library/papers/31515154 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42862366 | Stage-specific prognostic value of PSA in prostate cancer: a multicentre KAMU-ON study. | World J Urol | 2026 | https://conductscience.org/library/papers/42862366 | PubMed |
| 42794629 | Targeting the Androgen Receptor and Associated Cofactors in Prostate Cancer: Novel Approaches and Future Perspectives. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42794629 | PubMed |
| 42527846 | DLL3-Targeted Strategies in Advanced Prostate Cancer: Current Evidence and Future Perspectives. | Drugs | 2026 | https://conductscience.org/library/papers/42527846 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41689691
GET https://conductscience.org/api/papers/v1/41689691/references?page=2